



## Speaker Bios

**John W. Erickson,**  
**Ph.D,** *Chief Scientific  
Officer, Sequoia*

Dr. Erickson co-founded Sequoia Pharmaceuticals, Inc. in December 2001 and serves as its Chief Scientific Officer. Dr. Erickson also served as an Acting Chief Executive Officer and President of Sequoia Pharmaceuticals. He is a recognized leader in the field of drug discovery and develops marketable therapeutic solutions to the urgent and growing threat to public health posed by drug resistant viral, bacterial and fungal diseases, with an initial emphasis on HIV/AIDS. ... Dr. Erickson has previously spearheaded innovative drug discovery programs in the pharmaceutical, government and biotechnology sectors that have resulted in the development of two drugs, Ritonavir and Lopinavir at Abbott Laboratories, and of TMC-114, now in clinical development at Johnson & Johnson. He established and directed the first multi-disciplinary antiviral drug discovery program at Abbott Laboratories. Dr. Erickson joined the National Cancer Institute in 1991, where he directed the Biomedical Supercomputing Center, and established the Structural Biochemistry Program, a multi-disciplinary research program focused on structure-based drug design. In 2000, Dr. Erickson established Tibotec, Inc., a U.S. affiliate of Tibotec-Virco Group NV. While at Tibotec, he spearheaded the development of TMC-114, a protease inhibitor, which was acquired by Johnson & Johnson and is in Phase II clinical trials. His research has spawned numerous drug discovery applications and spans therapeutic markets from HIV/AIDS and infectious diseases to cancer, and other life-threatening diseases. He serves as a Director of Sequoia Pharmaceuticals, Inc. Dr. Erickson has authored or co-authored over 140 scientific publications, and is a co-inventor on over twenty (20) patents in the field of drug discovery.

**Gloria Tavera** *NIH  
Research Fellow, UAEM*

Gloria is currently conducting malaria research as an intramural training fellow at the National Institute of Allergy and Infectious Diseases. In 2009, she graduated from the University of Florida with degrees in neurobiology, political science and public health. She co-founded a chapter of UAEM at the University of Florida and has been a member of the Coordinating Committee since 2006. She spent last year in Mexico as a Fulbright scholar researching the pathology of dengue hemorrhagic fever.

**Mukul Ranjan,**  
**Ph.D,** *Branch Chief,  
Immunology and  
Emerging Infections  
Branch office of  
Technology Development,  
National Institute of  
Allergy and Infectious  
Diseases (NIAID)*

Dr. Ranjan, is Branch Chief at NIAID's Office of Technology Development and represents NIAID in collaborations between the public, private academic and non-profit sectors.

Dr. Ranjan has extensive knowledge of intellectual property and U.S. patent laws, issues and procedures, and is a member of the US Patent Bar. He has worked at the U.S. Patent and Trademark Office (PTO) as a Biotechnology Patent Examiner dealing with receptors and cytokines. Before joining the PTO, Dr. Ranjan was a research scientist, at NIH studying gene regulation during early embryonic development and during cell differentiation in the brain and has published in numerous scientific journals.

Dr. Ranjan has a special interest in alleviating the global disease burden due to infectious disease and is keenly interested in international collaborations and development issues. He has attended and spoken at a number of international symposia on technology transfer in the developing world, including the U.S.-Egypt "Investment in Biotechnology" workshop (Cairo, Egypt) and the U.S.-India Technology Managers Symposia in 2001 and 2002 (Delhi, India), the US Licensing Executives Society, 2005 Annual Meeting on "Emerging Strategies and Structures in Global Health", the AUTM 2006 Annual Meeting where he chaired a panel on "Drugs and Vaccines for Global Health: Challenges and Strategies," the NIH/Nordic meeting, 2006 (Helsinki, Finland). He has also lectured on Patent Law to students in a Biotechnology Law and Policy Foundation for

the Advancement of Education on the Sciences (FAES) class. Dr. Ranjan has a M.S. from the University of New Delhi and a Ph.D. from the University of Notre Dame.

**Dr. Kishor M. Wasan**, *University of British Columbia*

Dr. Wasan is a Distinguished University Scholar Professor & Founder of the Neglected Global Diseases Initiative at the University of British Columbia in Vancouver, BC, Canada. In the 14 years that Dr. Wasan has been an independent researcher at UBC, he has published over 180 peer-reviewed articles and 225 abstracts in the area of lipid-based drug delivery and lipoprotein-drug interactions. His work was recently highlighted in the January 2008 Issue of Nature Reviews, Drug Discovery.

Dr. Wasan was one of the recipients of the 1993 American Association of Pharmaceutical Scientists (AAPS) Graduate Student Awards for Excellence in Graduate Research in Drug Delivery, the 2001 AAPS New Investigator Award/Grant in Pharmaceutics and Pharmaceutics Technologies, the 2002 Association of Faculties of Pharmacy of Canada New Investigator Research Award and recently was named an AAPS fellow in 2006. In addition, Dr. Wasan was awarded a Canadian Institutes of Health Research University-Industry Research Chair in Pharmaceutical Development (2003-2008), was named a University Distinguished Scholar in April 2004 received the 2007 AAPS Award for Outstanding Research in Lipid-Based Drug Delivery and the 2008 AFPC-Pfizer Research Career Award. In April 2009 Dr. Wasan was named CIHR/iCo Therapeutics Research Chair in Drug Delivery for Neglected Global Diseases and on September 30, 2010 Dr. Wasan was named a Fellow of the Canadian Academy of Health Sciences. Currently Dr. Wasan's research is supported by several grants from The Canadian Institutes of Health Research, several pharmaceutical companies and the National Cancer Institute of Canada-Clinical Trials Group.

**Rita Khanna, Ph.D., J.D.**, *General Counsel for Aeras Global TB Vaccine Foundation*

Dr. Khanna has broad ranging engagement and experience on issues of global health, especially on diseases affecting developing countries. She was previously the Director of Technology Transfer at the University of Maryland Biotechnology Institute and has worked at the National Institutes of Health (NIH) in the Office of Technology Transfer, National Cancer Institute's Technology Development and Commercialization Branch and the Office of the General Counsel. In addition to her technology transfer and legal experience, she has extensive scientific research experience at NIH, the Smithsonian Institution, in academia and private industry. Dr. Khanna has published extensively, including most recently as co-editor of a book titled "Technology Transfer in Biotechnology". She received her Ph.D. from the University of Illinois and her J.D. from the University of Maryland. She serves on the Board of several organizations including the Centre for Development and Population Activities (CEDPA) and Public Interest Intellectual Property Associates (PIIPA), and was an Advisor to the World Bank's Development Gateway, Program Committee Member of the Association of University Technology Managers (AUTM), Scientific Advisor to the Institute for One World Health and Co-Chair of the first Gordon Conference on technology transfer titled "Global Aspects of Technology Transfer: Biotechnology".

**Dr. Neeraj Mistry**  
*Sabin Vaccine Institute*

Dr. Mistry is a Managing Director at Global Network for Neglected Tropical Diseases. A public health physician, Dr. Mistry was a founding member and former vice president of the Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria (GBC). While at GBC, he developed the Business AIDS Methodology (BAM™) and Best Practice AIDS Standard (BPAS™) and conceptualized and led GBC's work on co-investment and public-private partnerships with the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund.

Following the completion of his medical training at the University of the Witwatersrand Medical School in Johannesburg, South Africa, Dr. Mistry focused on HIV/AIDS, occupational health, family practice and sexual and reproductive health. Dr. Mistry also worked at the National Health Service (NHS) in London and with Merck & Co. Inc. dealing with public affairs for Europe, the Middle East and Africa. He holds a Master's degree in health policy and economics from the

London School of Economics and Political Science. He is currently reading for a Masters in Liberal Arts at Johns Hopkins.

**Adam Richman,**  
**Ph.D.,** *Director,*  
*Mosquito Production,*  
*Sanaria Inc*

Dr. Richman is a senior scientist at Sanaria Inc. Before joining Sanaria, Dr. Richman worked as an Associate Director at Translational Neuroscience Program, Baltimore VAMC (2003 -2005) and as Program Officer, Medical Research Service, Office of Research and Development at Veterans Health Administration (2001-2003). Dr. Richman also worked as an Assistant professor at University of Maryland (1999-2001) and Staff Scientist, European Molecular Biology Laboratory, Heidelberg Germany (1994-1999). Between 1990-1193 Dr Richma did his Post-doc at Harvard. Dr. Richard holds Ph.D in biology from Yale university (1990) and BA in Biology (1982) from University of California, Santa Cruz.

**James Love,** *Director,*  
*Knowledge Ecology*  
*International*

Mr. Love is the Director of Knowledge Ecology International. Mr. Love is also the U.S. co-chair of the Trans-Atlantic Consumer Dialogue Intellectual Property Policy Committee, chair of Essential Inventions, an advisor to the X-Prize Foundation on a prize for TB diagnostics, and a member of the UNITAID Expert Group on Patent Pools, the MSF Working Group on Intellectual Property, the Stop-TB Partnership working group on new drug development, and the Internet Governance Forum (IGF) Dynamic Coalition on Open Standards. He advises UN agencies, national governments, international and regional intergovernmental organizations and public health NGOs, and is the author of a number of articles and monographs on innovation and intellectual property rights. In 2006, Knowledge Ecology International received a MacArthur Award for Creative and Effective Institutions.

Mr. Love was previously Senior Economist for the Frank Russell Company, a lecturer at Rutgers University, and a researcher on international finance at Princeton University. He holds a Masters of Public Administration from Harvard University's Kennedy School of Government and a Masters in Public Affairs from Princeton's Woodrow Wilson School of Public and International Affairs.

**Dr. Paul Wilson,**  
*Assistant Professor of*  
*Clinical Population and*  
*Family Health, Columbia*  
*University*

Dr. Wilson, assistant professor of Clinical Population and Family Health at Columbia University is a scientist and economist working to bring new drugs and vaccines to developing countries. Currently a consultant to NGOs and international organizations, Dr. Wilson has been director of Policy Analysis at the International AIDS Vaccine Initiative and associate director of the Earth Institute at Columbia University. At the Mailman School of Public Health, he has worked on several aspects of international AIDS policy and on strategies for reaching the Millennium Development Goals. He is the lead author of the UN Millennium Project report Combating AIDS in the Developing World. Before moving to Columbia to work on global health policy, Dr. Wilson spent a number of years in basic science and held research positions at Harvard, Rockefeller University, and Cornell Medical College, where he was assistant professor of cell biology. Dr. Wilson holds degrees in Zoology, Economics, and Physics.

**Dr. Paul Converse,**  
*Research Associate, Johns*  
*Hopkins University*  
*School of Medicine*

Dr. Paul Converse is a Research Associate at the Division of Infectious Diseases at the Johns Hopkins School of Medicine. His research interests concern the interface of the pathogens, Mycobacterium tuberculosis and M. ulcerans, with human and experimental animal hosts. Studies in tuberculosis concern pathogenesis following infection with wild-type and gene deletion mutants as well as the impact of the immune system on the response to chemotherapeutic agents. Studies on M. ulcerans, the causative agent of Buruli Ulcer, have focused on differential response to vaccination in different mouse strains and the evaluation of novel chemotherapy regimens in comparison with the new WHO standard of rifampin and streptomycin. Before working on the pathogenesis of tuberculosis, he studied host immunity to Mycobacterium leprae, the causative agent of leprosy. Most of his work in this field was carried out during a four-year stint at the Armauer Hansen Research Institute in Addis Ababa, Ethiopia.

**Sandeep Kishore,  
MSc**

*UAEM Board of  
Directors*

Mr. Kishore is enrolled in the Weill Cornell Medical College/ Rockefeller/Sloan-Kettering Institute Tri-Institutional MD-PhD program. Sandeep plans a career in global public health as a physician-scientist and public health advocate. His scientific research concerns characterizing gene activation in the parasite responsible for malaria. He has been involved in global health efforts through leading a global student-led campaign against neglected tropical diseases, integrating global health and neglected tropical disease issues into current medical school curricula and successfully advocating for the inclusion of a cholesterol-lowering statin on the World Health Organization's Model List of Essential Medicines in 2007. In 2009, he served as an invited speaker for the National Academy of Sciences Institute of Medicine Board on Global Health and in 2010, he was nominated as a civil society delegate to the United Nations. He currently serves on the Board of the global NGO Universities Allied for Essential Medicines (UAEM). His health-related work has been featured in the popular press (Scientific American and The Scientist) and he is a co-author of a chapter of the forthcoming textbook Global Chronic Disease published by the Oxford University Press. His technical writings in public health have appeared in a broad range of journals including PLoS Medicine, the Nature Reviews series, Clinical Pharmacology & Therapeutics and the Global Forum for Health Research. He is the first The Lancet Prize winner for community service and is a 2008 Paul & Daisy Soros Fellowship for New Americans recipient.

**Heather Joseph**

*Executive Director,  
SPARC*

Heather Joseph serves as the Executive Director of the Scholarly Publishing and Academic Resources Coalition (SPARC), an international coalition of academic & research libraries whose mission is to expand the cost-effective, digital dissemination of scholarly and scientific research results. As SPARC's Director, Heather focuses on enabling new publishing models, digital archives and open access policies on both the national and international level.

Ms. Joseph is also the convener of the Alliance for Taxpayer Access, a broad coalition of universities, patients advocacy groups, consumer groups, and student organizations who work to ensure that results of publicly funded research are openly accessible to the public. The group has been a leading voice in promoting U.S. open access legislation, including the landmark public access policy issued by the National Institutes of Health (NIH).

Prior to joining SPARC, she spent 15 years as a publishing executive in both commercial and not-for-profit publishing organizations. She is an active participant a variety of projects and committees at the Department of Energy, NASA and the NSF, and serves on the Board of Directors of numerous not-for-profit organizations. She recently completed a term as the President of the Society for Scholarly Publishing, and is a frequent speaker and writer on scholarly communications in general, and on open access in particular.

**Zakir Thomas**

*Project Director, Open  
Source Drug Discovery,  
CSIR, India*

Mr. Zakir Thomas is the Project Director, Open Source Drug Discovery (OSDD) Project of CSIR ([www.osdd.net](http://www.osdd.net)). He is responsible for overall coordination and implementation of the project. He heads the Director General's Technical Cell, CSIR, leading a team which provides technical and policy inputs to Director General, CSIR.

He is an officer of the Indian civil service with over 20 years of experience in government in finance, administration and legal areas. He has been the Registrar of Copyrights, government of India and a Deputy Secretary to the government of India in the Ministry of Human Resource and Development. He has been involved in managing important e-governance projects of government of India. He has represented the government of India in several international forums.

He holds an MS in Physics, LLB from Delhi University and LLM from Franklin Pierce Law Centre, US and has several publications.

**Dr. Rebecca  
Goulding, ISIS**

Rebecca Goulding joined ISIS in 2009 as a postdoctoral fellow and currently works on the potential of alternative intellectual property strategies, regulatory and financial innovation policy to promote neglected disease drug discovery and development. Prior to this she was a postdoctoral fellow (2008-2009) with the Intellectual Property Policy and Research Group (IPPRG) at the W. Maurice Young Centre for Applied Ethics, where she worked alternative intellectual property regimes and upstream genomic research. Rebecca completed her BSc in genetics and MSc in hematology/oncology at the University of Dublin, Trinity College. She continued her graduate studies at the Terry Fox Laboratory, BC Cancer Research Centre, finishing her PhD in genetics at University of British Columbia in 2008. For her thesis, Rebecca studied Ras protein signaling pathways in lymphocytes and the molecular genetics of leukemia development. During the last years of her PhD, she became involved with a student group called Universities Allied for Essential Medicines (UAEM), which inspired her interest in global health research, particularly in the area of neglected disease drug research.

**Matthew Todd,**  
*The Synaptic Leap*

Dr. Todd is a Senior Lecturer at the School of Chemistry, the University of Sydney. Prior to that he was a lecturer in Organic Chemistry at Department of Chemistry Queen Mary, University of London (2001-2005). Matthew Todd received his PhD from Cambridge University where he worked on encoding and linker strategies for combinatorial chemistry. He was also a postdoctoral fellow at Berkeley, University of California between 1999-2000 where he worked on divergent syntheses of peptidomimetic scaffolds. He has a number of research publications.

**Rachel Kiddell-  
Monroe**  
*Chair of UAEM  
Board of Directors*

Rachel has worked in the humanitarian field for over 20 years, served as the Special Assistant for the East Timor campaign at the United Nations and has extensive field experience in Africa and Latin America working for Doctors Without Borders (MSF). She served as head of mission in Djibouti and lead emergency humanitarian missions in Rwanda (1994-1995) and the Democratic Republic of Congo (1993-1994, 1996-1997). She started up an MSF advocacy office in Canada and spearheaded MSF's Regional humanitarian and advocacy coordination office in Latin America. Upon returning to Montreal, she headed up MSF's Access to Medicines Campaign in Canada where she gained notoriety and respect for her groundbreaking work on the Canadian initiative to allow the export of generics to developing countries under the 2003 World Trade Organization patent waiver. In 2007, she was appointed to chair the UAEM Executive Board and has a particular interest in the international expansion of UAEM. She has also consulted for the Drugs for Neglected Diseases initiative (DNDi), is a member of the United Kingdom Law Society and is currently co-teaching an international development course at McGill University.

**Ethan Guillen**  
*UAEM Executive  
Director*

Ethan Guillen is the Executive Director of Universities Allied for Essential Medicines and has expertise in the role of universities and publicly funded research institutions in the access to medicines crisis. Ethan's work promotes global access to medicines and encourages publicly funded institutions to promote their innovations in the public interest.

## Moderator Bios:

**Aria Ilyad Ahmad,**  
*UAEM – University of  
Toronto*

Aria is a PhD candidate in global pharmaceutical policy at the University of Toronto. He is a research associate at the Laboratory for Collaborative Diagnostics (LCD) and the Initiative for Drug Equity & Access (IDEA), having published in drug quality evaluation in poorly regulated pharmaceutical supply chains. As the president of the UAEM chapter at the University of Toronto, Aria co-organized a two day UAEM-IDEA workshop in 2009 on 'Universities, Innovation and Global Medicine Access' that produced an academic Statement of Principles and Commitments. He has also appeared as a witness before the Canadian Senate to reform Canada's Access to Medicines Regime. A previous recipient of the Centre of International Health fellowship program in Namibia, Aria will also be the inaugural UAEM-Medicines Sans Frontiers (MSF) fellow at the Access to Medicines Campaign in Delhi, India in 2011.

**Laura Musselwhite,**  
*UAEM – Duke  
Medical School, Johns  
Hopkins School of Public  
Health*

Laura is currently earning an MD at Duke University and Masters of Public Health at Johns Hopkins Bloomberg School of Public Health. In 2010, she completed a CRTP Fellowship at the National Institutes of Health assessing the use of clinical factors and biomarkers as predictors of adverse outcomes in HIV-infected patients. While in the DC area, she led several initiatives within UAEM's AffordableMedsNow campaign in collaboration with other consumer protection groups to address biologic drug provisions within health reform bills. Interests outside of UAEM include bluegrass music, sweet tea, and free-lance writing. Laura is looking forward to moving UAEM's Science, Innovation, and Neglected Diseases Working Group agenda forward!

**Karolina Maciag**  
*UAEM - Harvard  
Medical School/MIT-  
HST*

Karolina is a fifth-year MD/PhD Candidate at Harvard Medical School/MIT-HST. She graduated from Harvard College with a degree in Biochemical Sciences in 2004, with a focus on research in computational biology. She currently studies innate immunity to intracellular bacteria, including tuberculosis. As a Radcliffe Volunteer Fellow, she worked with local health promoters and visiting medical teams in indigenous Guatemalan villages for six months. Karolina is a member of the Harvard and MIT chapters of UAEM and was closely involved with initial outreach to the Harvard technology transfer office and faculty as well as the ensuing negotiation.

**Ankush Sharma Sana**  
*and UAEM –  
University of Michigan*

Born in northern India and raised in California's 'central valley', Mr. Sharma is interested in the marriage of public health and innovation in technology as it applies to strengthening health systems and the delivery of care in the U.S. and globally. Sharma has worked on issues from access to healthcare for undocumented and refugee immigrants to coordinating Katrina relief efforts for his alma mater, but wakes up looking forward to working on Sana, a cell phone-based clinical information system that offers open source data collection and collaboration platforms for clinical research and best practice health care delivery for underserved rural populations. Mr. Sharma was educated at Berkeley, Harvard and Michigan.